Skip to content Skip to footer
Subscribe Now
NEWS

Tolion Health AI Launches AI-Powered Tolion Brain Coach App for Brain Health, Longevity, and Prevention of Alzheimer’s Disease

Shots: Tolion Health AI has launched Tolion Brain Coach, a new App within its Brain Health Platform designed to deliver personalized, preventive, & predictive insights for cognitive health using AI-driven analytics & wearable-device data Platform leverages Tolion’s Knowledge Engine & Brain Score to generate tailored recommendations aimed at strengthening cognitive resilience & reducing neurodegenerative disease…
May 12, 2026

Read more

NEWS

Roche to Acquire PathAI for ~$1.05B

Shots: Roche has entered into a definitive merger agreement to acquire PathAI, building on their 2021 partnership, which scaled up in 2024 to incl. the development of AI-enabled companion diagnostic algorithms As per the deal, Roche will acquire PathAI for $750M upfront & ~$300M in additional milestone payments; closing is expected in H2’26 The acquisition…
May 7, 2026

Read more

NEWS

Artera Secures FDA Clearance for AI-Based Breast Cancer Risk Tool

Shots: The US FDA has granted clearance to ArteraAI Breast, a digital pathology-based risk stratification tool for early-stage HR+ /HER2- breast cancer, expanding the company’s oncology AI platform beyond prostate cancer ArteraAI Breast uses multimodal AI combining digitized histopathology images & clinical data to generate an AI-derived risk score predicting distant metastasis risk, helping clinicians…
May 7, 2026

Read more

NEWS

Caris Launches Caris MI Clarity for AI-Powered Breast Cancer Recurrence Risk Assessment

Shots: Caris has launched Caris MI Clarity, an AI-driven prognostic test for postmenopausal pts with HR+/HER2-, node-negative early-stage breast cancer, designed to assess both early (0–5yrs.) & late (5–15yrs.) distant recurrence risk from a single test at diagnosis The test leverages Caris’ multimodal dataset, computational pathology & AI-driven ML to analyze digitized H&E slides and…
May 6, 2026

Read more

NEWS

Profluent Signs ~$2.25B Pact with Eli Lilly to Advance AI-Designed Recombinases for Genetic Medicines

Shots: Profluent has entered into a multi-program strategic research collaboration with Eli Lilly to develop & commercialize custom site-specific recombinases to address diseases with unmet needs As per the deal, Profluent will use its AI models to design & optimize site-specific recombinases for multiple genomic targets, while Lilly will gain exclusive rights to selected assets…
April 29, 2026

Read more

NEWS

Merck Partners with Google Cloud in ~$1B Deal to Build AI-Enabled Enterprise Platform

Shots: Merck partnered with Google Cloud in a multi-year deal worth up to $1B to deploy an AI-driven agentic platform across R&D, manufacturing, commercial, and corporate functions The collaboration will integrate advanced AI tools, incl. Gemini Enterprise, to enhance productivity, digitize data, & support Merck’s global workforce of ~75,000 employees The partnership aims to accelerate…
April 23, 2026

Read more

NEWS

Astellas Exercises Option to License Dyno’s AAV Capsid for AI-Designed Gene Delivery

Shots: Dyno Therapeutics has reported that Astellas has exercised its option to license an AI-engineered AAV capsid for skeletal muscle delivery, marking the first licensed asset from their 2021 collaboration The capsid, designed using Dyno’s AI models trained on large-scale in vivo data, demonstrates improved muscle targeting at lower doses, addressing key safety & manufacturing…
April 9, 2026

Read more

NEWS

Merck Signs ~$838M AI-Driven Antibody Discovery Deal with Infinimmune

Shots: Infinimmune has partnered with Merck to discover & develop antibody candidates against multiple undisclosed targets selected by Merck using Infinimmune’s human-first antibody discovery platform As per the deal, Infinimmune will use its Anthrobody discovery platform & Glimpse antibody language model to discover & optimize antibodies from human immune repertoires, enabling large-scale B-cell screening to…
April 1, 2026

Read more

NEWS

Insilico Medicine Expands AI-Driven CNS Collaboration with Tenacia in a ~$94.75M Deal

Shots: Insilico Medicine and Tenacia Biotechnology have expanded their AI-driven R&D collaboration to develop an additional CNS candidate with defined properties, advancing it to the preclinical candidate stage for neurological disorders The initial collaboration, launched in Mar 2025, combined Insilico’s Pharma.AI platform with Tenacia’s CNS expertise to develop BBB-permeable small-molecule inhibitors, with the program progressing…
March 27, 2026

Read more

NEWS

PRISM BioLab and Receptor.AI Partner to Develop a Drug Discovery Platform

Shots: PRISM has partnered with Receptor.AI to develop an AI-navigated, physics-guided platform for discovering orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins & complex receptor systems Collaboration will combine PRISM’s PepMetics Tech, 3D small molecules designed to mimic α-helix & β-turn motifs, with Receptor.AI’s AI-driven molecular design engine to identify hit, lead, &…
March 13, 2026

Read more

Load more